Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Nothing like some 'leaks' on the FDA Resubmission

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Apr 27, 2023 10:05am

133 Views

Post# 35416799

RE:RE:RE:RE:Nothing like some 'leaks' on the FDA Resubmission

While I am all for getting THTX to close above $1 per share for 10 consecutive trading days to take the potential for delisting from NASDAQ off the table, it would hardly be a disaster if it happened. Also, it is unlikey to happen until February 2024 if they fail to get the stock price higher. But the reason it would not be a disaster is it traded on the pink sheets for many years without any issues prior to being listed on NASDAQ. Now, I really don't want it to trade on the pink sheets again, as there are worthwhile advantages to owners of THTX if it is on NASDAQ, but it would not be a total disaster if it did.